

# Optimal Doses Per Vaccine Vial: A Global Conversation

Roundtable 14<sup>th</sup> TechNet Conference Bangkok, Thailand 13 May 2015

## **Dose Per Vial – A Global Conversation**

- Initiate a global discussion concerning the number of doses per vial and optimal decisions
- We will seek to examine several aspects of this complex issue:
  - Programmatic implications
  - Market implications
  - Impact on timely and equitable coverage
  - Impact on wastage and cost



# **Overview:**

## **Dose Per Vial – A Global Conversation**

- Synthesize existing data, identify gaps
- Stakeholder engagement (global and country levels)
- Convene the stakeholder meeting



### Phase One: Synthesizing the Available Data

- Synthesize existing data and studies currently ongoing
  - Kenya Mixed Presentation, WHO Session Size
- Identify gaps in available data
  - In-depth interviews with key partners
  - Questionnaire for EPI Staff



### Phase One: Stakeholder Engagement

- Getting input from global partners prior to the meeting to help develop the agenda
- Engaging EPI staff to provide country-level perspectives
- Using opportunities where stakeholders will be gathered
  - WHO EPI Managers Meetings
  - IAIM Inaugural Conference
  - TechNet



### **Phase One: Convening Stakeholder Meeting**

- Sharing existing data and identifying knowledge gaps
- Mapping stakeholder mandates, values, objectives, and concerns
- Reaching agreement on a process for partners and countries to determine optimal vial size



# Phase Two: Pursue initiatives to address the identified data gaps

- Data collection, analysis and aggregation of information
- Further stakeholder collaboration to develop of potential recommendations, guidelines, tools and/or policies for optimal dose per vial approaches
- Share data with suppliers, others interested in improvement in vaccine development







Q1: Please select one category from this list that most closely represents your job or affiliation

- A) Logistician
- B) Industry
- C) Immunization / Public Health Manager
- D) Partner organization
- E) Other

Q2: Please select the income level associated with the country where you work or one where you are familiar with vaccine delivery:

- A) Lower income country
- B) Lower middle income country
- C) Upper middle income country
- D) High income country

Think about the measles (or MR) vaccine and answer the following two questions based on what you know about your **routine immunization program** (or choose a low or middle income country program which you know well)



Q3: What is the average fixed session frequency for measles vaccine?

- A) Daily
- B) Whenever an eligible child arrives
- C) When session size reaches a certain number
- D) Once per week
- E) 2, 3, or 4 times per week
- F) Once per month

Q4: If your program had the option of the following presentation of measles (or MR) vaccine, which would you prefer? (choose one)

- A) 1-dose vial only
- B) 5-dose vials only
- C) 10-dose vials only
- D) A mixture of presentations

# We want to hear from you!

# Please fill out a questionnaire and/or contact

### Alexis Heaton or Rachel Feilden here at TechNet or by e-mail (immunization@jsi.com) to discuss this topic in more detail

